drugset / Trial / NCT05594797
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2
Recruiting
100 enrolled
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University · collabShanghai Changzheng Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2025-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human BCMA Targeted T Cells Injection | Cell therapy | 6e+06 cells/kg | Other |